KRYS Krystal Biotech Inc

Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference

Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference

PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14.

Krish Krishnan, Chairman and Chief Executive Officer, will deliver a presentation and host investor meetings on September 13.

A webcast of the presentation will be available beginning at 2:30pm ET on Tuesday, September 13 and will be posted on the Investor section of the Company’s .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit , and follow @KrystalBiotech on and .

CONTACT:

Investors and Media:                                                                

Meg Dodge                                                      

Krystal Biotech                                                    

                                            

Source: Krystal Biotech, Inc.



EN
08/09/2022

Underlying

KRYSKrystal Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Krystal Biotech Inc

 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at BofA Securities 2025 Health Care Confere...

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 11:20 am PT on Wednesday, May 14, 2025 and will be posted on the Investors section of...

May 7, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces First Quarter 2025 Financial and Operating R...

Krystal Biotech Announces First Quarter 2025 Financial and Operating Results VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular complications of DEB, and aesthetics Strong balance sheet, ending the quarter with $765.3 million in cash and investments PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) today reported financ...

May 6, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces European Commission Approval of VYJUVEK® for...

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK® (beremagene geperpavec-...

April 28, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at Upcoming Scientific Conferences

Krystal Biotech to Present at Upcoming Scientific Conferences PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June. Presentation details are outlined below. American Society of Gene & Cell Therapy (ASGCT) 28th Annual MeetingInvited Oral Presentation Title: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary diseasePresenter: Trevor Parry, PhDDate and Time: May 17, 202...

April 24, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Report First Quarter 2025 Financial Results on May ...

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For those unabl...

April 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch